Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome

Human Pathology

Volumn 54, Issue , 2016, Pages 157-164

  Garg, Kanika ^a   Maurer, Margarita ^a   Griss, Johannes ^a   Brüggen, Marie Charlotte ^a   Wolf, Ingrid H ^b   Wagner, Christine ^a   Willi, Niels ^c   Mertz, Kirsten D ^c   Wagner, Stephan N ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Kantonsspital Liestal   (Switzerland)

Author keywords

CD20; Melanoma; Prognosis; Tumor microenvironment; Tumor associated B cells (TAB); Tumor infiltrating lymphocytes

Indexed keywords

BIOLOGICAL MARKER; CD19 ANTIGEN; CD20 ANTIGEN; MESSENGER RNA; RNA; CD19 MOLECULE, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CUTANEOUS MELANOMA; DIGITAL IMAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; SURVIVAL ANALYSIS; TUMOR ASSOCIATED B CELL; TUMOR MICROENVIRONMENT; AUSTRIA; CLINICAL TRIAL; FEMALE; GENETIC DATABASE; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SECONDARY; SKIN TUMOR; SWITZERLAND; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD19; ANTIGENS, CD20; AUSTRIA; B-LYMPHOCYTES; BIOMARKERS, TUMOR; DATABASES, GENETIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SWITZERLAND; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 84971505166     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.03.022     Document Type: Article

References (36)

1. B.H. Nelson CD20 + B cells: the other tumor-infiltrating lymphocytes J Immunol 185 2010 4977 4982
2. M. Linnebacher, and C. Maletzki Tumor-infiltrating B cells: the ignored players in tumor immunology Oncoimmunology 1 2012 1186 1188
3. N.I. Affara, B. Ruffell, T.R. Medler, and et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas Cancer Cell 25 2014 809 821
4. M. Ammirante, J.L. Luo, S. Grivennikov, S. Nedospasov, and M. Karin B-cell-derived lymphotoxin promotes castration-resistant prostate cancer Nature 464 2010 302 305
5. S. Shalapour, J. Font-Burgada, G. Di Caro, and et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy Nature 521 2015 94 98
6. F. Hillen, C.I. Baeten, A. van de Winkel, and et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma Cancer Immunol Immunother 57 2008 97 106
7. G. Erdag, J.T. Schaefer, M.E. Smolkin, and et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma Cancer Res 72 2012 1070 1080
8. J.M. Taube, A. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
9. P. Hersey, E. Murray, J. Grace, and W.H. McCarthy Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma Pathology 17 1985 385 391
10. M.R. Hussein, D.A. Elsers, S.A. Fadel, and A.E. Omar Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions J Clin Pathol 59 2006 316 324
11. A. Ladanyi, J. Kiss, A. Mohos, and et al. Prognostic impact of B-cell density in cutaneous melanoma Cancer Immunol Immunother 60 2011 1729 1738
12. M. Martinez-Rodriguez, A.K. Thompson, and C. Monteagudo A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma Histopathology 65 2014 726 728
13. C. Fremd, F. Schuetz, C. Sohn, P. Beckhove, and C. Domschke B cell-regulated immune responses in tumor models and cancer patients Oncoimmunology 2 2013 e25443
14. S. Shah, A.A. Divekar, S.P. Hilchey, and et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells Int J Cancer 117 2005 574 586
15. S. Inoue, W.W. Leitner, B. Golding, and D. Scott Inhibitory effects of B cells on antitumor immunity Cancer Res 66 2006 7741 7747
16. E. Ralfkiaer, K. Hou-Jensen, K.C. Gatter, K.T. Drzewiecki, and D.Y. Mason Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas Virchows Arch A Pathol Anat Histopathol 410 1987 355 361
17. S. Meyer, T.J. Fuchs, A.K. Bosserhoff, and et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts PLoS One 7 2012 e38222
18. L.M. McShane, D.G. Altman, W. Sauerbrei, and et al. Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
19. M.B. Lens, J.A. Newton-Bishop, and A.P. Boon Desmoplastic malignant melanoma: a systematic review Br J Dermatol 152 2005 673 678
20. M.A. Sedhom, M. Pichery, J.R. Murdoch, and et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice Gut 62 2013 1714 1723
21. A. Pinc, R. Somasundaram, C. Wagner, and et al. Targeting CD20 in melanoma patients at high risk of disease recurrence Mol Ther 20 2012 1056 1062
22. A.M. Bogusz, R.H. Baxter, T. Currie, and et al. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma Clin Cancer Res 18 2012 6122 6135
23. M.C. Bruggen, I. Klein, H. Greinix, and et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease Blood 123 2014 290 299
24. E. Cerami, J. Gao, U. Dogrusoz, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
25. C. Germain, S. Gnjatic, and M.C. Dieu-Nosjean Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity Front Immunol 6 2015 67
26. K.E. de Visser, L.V. Korets, and L.M. Coussens De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent Cancer Cell 7 2005 411 423
27. P.B. Olkhanud, B. Damdinsuren, M. Bodogai, and et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells Cancer Res 71 2011 3505 3515
28. E.L. Carpenter, R. Mick, A.J. Rech, and et al. Collapse of the CD27 + B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers Clin Cancer Res 15 2009 4277 4287
29. E. Barbera-Guillem, M.B. Nelson, B. Barr, and et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion Cancer Immunol Immunother 48 2000 541 549
30. A. Tumanov, D. Kuprash, M. Lagarkova, and et al. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues Immunity 17 2002 239 250
31. S. Mandruzzato, A. Callegaro, G. Turcatel, and et al. A gene expression signature associated with survival in metastatic melanoma J Transl Med 4 2006 50
32. D. Bogunovic, D.W. O'Neill, I. Belitskaya-Levy, and et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival Proc Natl Acad Sci U S A 106 2009 20429 20434
33. V. Winnepenninckx, V. Lazar, S. Michiels, and et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome J Natl Cancer Inst 98 2006 472 482
34. Y. Iwata, T. Matsushita, M. Horikawa, and et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells Blood 117 2011 530 541
35. P.A. Blair, L.Y. Norena, F. Flores-Borja, and et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients Immunity 32 2010 129 140
36. J. Noh, W.S. Choi, G. Noh, and J.H. Lee Presence of Foxp3-expressing CD19(+)CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg) Immune Netw 10 2010 247 249